Johannes Gutenberg-Universität Mainz

Biontech Rna Pharmaceuticals Gmbh

Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz

Thomas Wölfel

Pierre Van Der Bruggen

Martina Fatho

Volker Lennerz

Dirk Schadendorf

Hakim Echchannaoui

Emmanuelle Wesarg

Serena Debo

Catherine Wölfel

Anette Paschen

Silke LÜBCKE

Eva Distler

Sabine Domning

Wolfgang Herr

Chris Schmidt

The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.

Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients

Growing community of inventors

Mainz, Germany

Thomas Wölfel